Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 45

Sort by

Sort Order Select

Journal Articles

Efficacy and safety of G-CSF in combination with venetoclax and azacitidine (VAG) in treatment of patients with higher-risk Myelodysplastic Syndromes (MDS)

Qingyu Xu, Ya-Lan Zhou, Ting Shi, Chuanying Geng, Wen Gao, Yun Leng, Yin Wu, Hong-Hu Zhu

Blood (2025) 146 (Supplement 1): 5646.

https://doi.org/10.1182/blood-2025-5646

Published: 2025

Journal Articles

High-throughput screening uncloaks actionable compounds for ttmv::rara AML

Zhanrui Cheng, Shu Sun, Jiayu Wang, Bei Yang, Gejia Cao, Wen Gao, Hong-Hu Zhu

Blood (2025) 146 (Supplement 1): 6109.

https://doi.org/10.1182/blood-2025-6109

Published: 2025

Journal Articles

USP28 inhibition upregulates CD20 via c-myc suppression and synergizes with anti-CD20 immunotherapy in B-cell lymphomas

Jieyu Xu, Shihui Mao, Pumin Zhang, Hong-Hu Zhu, Jiang-Jiang Qin, Haiyan Yang

Blood (2025) 146 (Supplement 1): 5093.

https://doi.org/10.1182/blood-2025-5093

Published: 2025

Journal Articles

Renal response of selinexor, bortezomib, pomalidomide, and dexamethasone in newly diagnosed multiple myeloma patients with renal impairment: A phase 2, prospective, multicenter study

Blood (2025) 146 (Supplement 1): 5830.

https://doi.org/10.1182/blood-2025-5830

Published: 2025

Journal Articles

Updated survival outcomes of pomalidomide/bortezomib/dexamethasone in newly diagnosed multiple myeloma with renal impairment: A prospective, open-label, multicenter, phase 2 study

Blood (2025) 146 (Supplement 1): 5818.

https://doi.org/10.1182/blood-2025-5818

Published: 2025

Journal Articles

Single-cell transcriptomic analysis reveals impaired immune profiles in elderly AML patients

Yebo Peng, Haixiao Zhang, Yingying Huo, Wen Gao, Ting Shi, Jianpeng Sheng, Hong-Hu Zhu

Blood (2025) 146 (Supplement 1): 1409.

https://doi.org/10.1182/blood-2025-1409

Published: 2025

Journal Articles

Vag regimen drives immune reprogramming and superior remission in older/unfit AML patients

Yingying Huo, Haixiao Zhang, Yebo Peng, Ting Shi, Ya-Lan Zhou, Chuanying Geng, Wenjing Li, Wen Gao, Wenming Chen, Hong-Hu Zhu

Blood (2025) 146 (Supplement 1): 769.

https://doi.org/10.1182/blood-2025-769

Published: 2025

Journal Articles

Selinexor-based regimens in triple-class exposed or refractory multiple myeloma: A real-world analysis of efficacy and safety in 18 patients

Wenjing Li, Yin WU, Chuanying Geng, Aijun Liu, Lefu Huang, Leng Yun, Yanru Zhang, Ying Tian, jing jia, Menghan Liu, Huijuan Wang, Guangzhong Yang, Hong-Hu Zhu, Wenming Chen, Wen Gao

Blood (2025) 146 (Supplement 1): 7590.

https://doi.org/10.1182/blood-2025-7590

Published: 2025

Journal Articles

Comprehensive profiling of highly heterogeneous FLT3-ITD variants reveals distinct drug response patterns in AML

Zhenyi Yi, Aili Chen, Lina Yan, Qiyi Chen, Hong-Hu Zhu, Qian-Fei Wang

Blood (2025) 146 (Supplement 1): 641.

https://doi.org/10.1182/blood-2025-641

Published: 2025

Journal Articles

Allograft inflammatory factor -1 is essential for acute monocytic leukemia infiltration

Aili Chen, Haiyang Hu, Hong-Hu Zhu, Gang Huang, Qian-Fei Wang

Blood (2025) 146 (Supplement 1): 5255.

https://doi.org/10.1182/blood-2025-5255

Published: 2025

Journal Articles

Efficacy and safety of aponermin-carfilzomib-dexamethasone-based regimens for relapsed/refractory multiple myeloma: A Phase 2 prospective multi-center study

Huixing Zhou, Chunrui Li, Baijun Fang, Lingzhi Yan, Aijun Liu, Peiling Zhang, Yang Liu, Xiaoqi Qin, Huanxin Zhang, Wei Zhou, Hong-Hu Zhu, Leng Yun, Yin WU, Yi Wang, Wenming Chen, Guangzhong Yang

Blood (2025) 146 (Supplement 1): 2271.

https://doi.org/10.1182/blood-2025-2271

Published: 2025

Journal Articles

First results of aponermin(Apo) improving teclistamab (tec)/talquetamab (tal) in patients (pts) with Relapsed/Refractory multiple myeloma (RRMM)

Lefu Huang, Yuechen Zhang, Huijuan Wang, Wenjing Li, Yanru Zhang, Menghan Liu, Ying Tian, Zunmin Zhu, Hong-Hu Zhu, Wenming Chen, Aijun Liu

Blood (2025) 146 (Supplement 1): 7576.

https://doi.org/10.1182/blood-2025-7576

Published: 2025

Journal Articles

A novel kinase-related gene signature predicts the survival and therapeutic responses of Acute Myeloid Leukemia

Haibo Yu, Yingying Huo, Haixiao Zhang, Wen Gao, Hong-Hu Zhu

Blood (2025) 146 (Supplement 1): 7011.

https://doi.org/10.1182/blood-2025-7011

Published: 2025

Journal Articles

Daratumumab-based therapy for newly diagnosed multiple myeloma patients with renal impairment：a multicenter retrospective study from China

Blood (2025) 146 (Supplement 1): 7546.

https://doi.org/10.1182/blood-2025-7546

Published: 2025

Journal Articles

A multivariable prediction model for early mortality in multiple myeloma patients with renal impairment

Menghan Liu, Wen Gao, Wenrong Huang, Xinan Cen, Yuan Jian, Huixing Zhou, jing jia, Wenming Chen, Hong-Hu Zhu

Blood (2025) 146 (Supplement 1): 5766.

https://doi.org/10.1182/blood-2025-5766

Published: 2025

Journal Articles

Comprehensive Clinical and Molecular Characterization Reveals Rara As the Most Frequent Torque Teno Mini Virus Insertion Site and Defines a Distinct Ttmv::Rara Driven APL-like Leukemia Subtype

Blood (2024) 144 (Supplement 1): 1547.

https://doi.org/10.1182/blood-2024-202323

Published: 2024

Journal Articles

Single-Cell RNA Sequencing Uncovers Distinct Molecular Characteristics and Immune Suppression Profiling of AML with Retinoic Acid Receptor γ Rearrangement

Qing-Yu Xu, Shu Sun, Yebo Peng, Yingying Huo, Ting Shi, Wen Gao, Hong-Hu Zhu

Blood (2024) 144 (Supplement 1): 5724.

https://doi.org/10.1182/blood-2024-204959

Published: 2024

Journal Articles

Critical role of tripartite fusion and LBD truncation in certain RARA - and all RARG -related atypical APL

Blood (2024) 144 (14): 1471–1485.

https://doi.org/10.1182/blood.2024023883

Published: 2024

Includes: Supplemental data

Journal Articles

Mitoxantrone Hydrochloride Liposome, Bortezomib, and Dexamethasone- Based Regimen in Multiple Myeloma Patients with Extramedullary Plasmacytoma: A Pilot Study

Yuan Jian, Nian Liu, Yan-Ru Zhang, Wen Gao, Wen-Ming Chen, Hong-Hu Zhu, Yin Wu

Blood (2023) 142 (Supplement 1): 6650.

https://doi.org/10.1182/blood-2023-188304

Published: 2023

Journal Articles

APL: Nemo finds its sea anemone

Qian-Fei Wang, Hong-Hu Zhu

Blood (2022) 140 (22): 2311–2312.

https://doi.org/10.1182/blood.2022018020

Published: 2022

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Efficacy and safety of G-CSF in combination with venetoclax and azacitidine (VAG) in treatment of patients with higher-risk Myelodysplastic Syndromes (MDS)

High-throughput screening uncloaks actionable compounds for ttmv::rara AML

USP28 inhibition upregulates CD20 via c-myc suppression and synergizes with anti-CD20 immunotherapy in B-cell lymphomas

Renal response of selinexor, bortezomib, pomalidomide, and dexamethasone in newly diagnosed multiple myeloma patients with renal impairment: A phase 2, prospective, multicenter study

Updated survival outcomes of pomalidomide/bortezomib/dexamethasone in newly diagnosed multiple myeloma with renal impairment: A prospective, open-label, multicenter, phase 2 study

Single-cell transcriptomic analysis reveals impaired immune profiles in elderly AML patients

Vag regimen drives immune reprogramming and superior remission in older/unfit AML patients

Selinexor-based regimens in triple-class exposed or refractory multiple myeloma: A real-world analysis of efficacy and safety in 18 patients

Comprehensive profiling of highly heterogeneous FLT3-ITD variants reveals distinct drug response patterns in AML

Allograft inflammatory factor -1 is essential for acute monocytic leukemia infiltration

Efficacy and safety of aponermin-carfilzomib-dexamethasone-based regimens for relapsed/refractory multiple myeloma: A Phase 2 prospective multi-center study

First results of aponermin(Apo) improving teclistamab (tec)/talquetamab (tal) in patients (pts) with Relapsed/Refractory multiple myeloma (RRMM)

A novel kinase-related gene signature predicts the survival and therapeutic responses of Acute Myeloid Leukemia

Daratumumab-based therapy for newly diagnosed multiple myeloma patients with renal impairment：a multicenter retrospective study from China

A multivariable prediction model for early mortality in multiple myeloma patients with renal impairment

Comprehensive Clinical and Molecular Characterization Reveals Rara As the Most Frequent Torque Teno Mini Virus Insertion Site and Defines a Distinct Ttmv::Rara Driven APL-like Leukemia Subtype

Single-Cell RNA Sequencing Uncovers Distinct Molecular Characteristics and Immune Suppression Profiling of AML with Retinoic Acid Receptor γ Rearrangement

Critical role of tripartite fusion and LBD truncation in certain RARA - and all RARG -related atypical APL

Mitoxantrone Hydrochloride Liposome, Bortezomib, and Dexamethasone- Based Regimen in Multiple Myeloma Patients with Extramedullary Plasmacytoma: A Pilot Study

APL: Nemo finds its sea anemone

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only